Literature DB >> 25531953

The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece.

Georgios P Karamanolis1, George L Daikos, Dimitrios Xouris, Dimitrios Goukos, Ioanna Delladetsima, Spiros D Ladas.   

Abstract

BACKGROUND: Increasingly, over time, antibiotic resistance is considered a problem for the efficacy of H. pylori eradication treatment. The aim of our study was to evaluate the changes in clarithromycin and levofloxacin resistance of H. pylori strains in Greek patients in two different time periods (in 2000 and in 2010).
METHODS: Gastric biopsies of consecutive H. pylori-positive patients were investigated retrospectively. Mutations in H. pylori 23S rRNA and gyrA genes associated with resistance to clarithromycin and quinolones, respectively, were determined by allelic specific polymerase chain reaction.
RESULTS: In the first time period (2000), H. pylori resistance patterns were evaluated in 50 and in the second period (2010) in 57 patients. During the first time period 30 and 0% of patients were infected with clarithromycin- or quinolone-resistant strains, respectively. In the second time period (2010), the percentage of patients infected with clarythromycin or quinolone resistance strains increased to 42 and 5.3%, respectively.
CONCLUSIONS: Our study showed an increase in the prevalence of both clarithromycin and quinolones resistance of H. pylori. Although the resistance rate to quinolones increased over the years, it is relatively low justifying its use for the eradication of H. pylori infections.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25531953     DOI: 10.1159/000369898

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  7 in total

Review 1.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

2.  Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial.

Authors:  Sotirios D Georgopoulos; Vasilios Papastergiou; Beatriz Martinez-Gonzalez; Elias Xirouchakis; Ioannis Familias; Dionysis Sgouras; Andreas Mentis; Stylianos Karatapanis
Journal:  Ann Gastroenterol       Date:  2017-12-15

Review 3.  Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.

Authors:  Yi Hu; Yin Zhu; Nong-Hua Lu
Journal:  Front Cell Infect Microbiol       Date:  2017-05-05       Impact factor: 5.293

4.  Seven-day genotypic resistance-guided triple Helicobacter pylori eradication therapy can be highly effective.

Authors:  Vasilios Papastergiou; Nicoletta Mathou; Sophia Licousi; Aikaterini Evgenidi; Konstantina D Paraskeva; Athanasios Giannakopoulos; Pinelopi-Zoi Stavrou; Evangelia Platsouka; John A Karagiannis
Journal:  Ann Gastroenterol       Date:  2017-11-30

5.  Hellenic consensus on Helicobacter pylori infection.

Authors:  Sotirios D Georgopoulos; Spyridon Michopoulos; Theodoros Rokkas; Pericles Apostolopoulos; Evangelos Giamarellos; Dimitrios Kamberoglou; Andreas Mentis; Konstantinos Triantafyllou
Journal:  Ann Gastroenterol       Date:  2020-01-07

6.  Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment.

Authors:  Yingjie Ji; Hong Lu
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

7.  Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care?

Authors:  Christos Liatsos; Apostolis Papaefthymiou; Nikolaos Kyriakos; Marios Giakoumis; Jannis Kountouras; Michail Galanopoulos; Periklis Apostolopoulos; Sotirios D Georgopoulos; Christos Mavrogiannis; Aristomenis K Exadaktylos; David Shiva Srivastava; Theodore Rokkas; Michael Doulberis
Journal:  Medicina (Kaunas)       Date:  2020-03-18       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.